Title: Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas

Running title: PD-(L)1 Blockade with or without chemotherapy in lung adenocarcinomas

Authors: Arielle Elkrief, MD*[1,2,5], Joao M. Victor Alessi, MD*[3], Biagio Ricciuti, MD*[3], Samantha Brown, MS[4], Hira Rizvi, MS[5], Isabel R. Preeshagul, MD[5], Xinan Wang, PhD, MS[7], Federica Pecci, MD[3], Alessandro Di Federico, MD[3], Giuseppe Lamberti, MD[3], Jacklynn V. Egger, MSc[5], Jamie E. Chaft, MD[5], Charles M. Rudin, MD, PhD[5,6], Gregory J. Riely, MD, PhD[5,6], Mark G. Kris, MD[5,6], Marc Ladanyi, MD[1,2], Yuan Chen, PhD[4], Matthew D. Hellmann, MD[5,6] Ronglai Shen, PhD*[4], Mark M. Awad, MD, PhD*[3], Adam J. Schoenfeld, MD*[5,6]

Affiliations:
1. Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY
2. Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, NY
3. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
4. Memorial Sloan Kettering Cancer Center, Department of Epidemiology & Biostatistics, New York, NY
5. Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY
6. Weill Cornell Medical College, Department of Medicine, New York, NY, USA
7. Harvard T.H. Chan School of Public Health, Harvard Univeristy, Department of Environmental Health, Boston, MA

Corresponding author:
Adam J. Schoenfeld
1275 York Ave, New York, NY 10065
Phone: 6466084042
Email: schoenfa@mskcc.org

*Contributed equally

Manuscript word count: 3071

KEY POINTS

Question: What is the comparative effectiveness of first-line PD-(L)1 blockade (IO) versus combination IO with platinum-based chemotherapy (Chemotherapy-IO) in patients with PD-L1 positive advanced lung adenocarcinoma, in the context of key clinical and molecular features?

Findings: There were improvements in response rate and progression-free survival associated with Chemotherapy-IO compared to IO, however overall survival (OS) was not different in the overall population studied. Only the subgroup of never-smokers with PD-L1 $\geq$50% (6% of all patients) had improved OS with Chemotherapy-IO compared to IO. No subgroup had worse OS with Chemotherapy-IO and no genomic alterations predicted better OS with Chemotherapy-IO compared to IO.

Meaning: Our findings inform potential rational strategies to select and sequence PD-(L)1 blockade and platinum-based chemotherapy in the context of clinical and genomic factors. The addition of chemotherapy to PD-(L)1 blockade generally increases the probability of initial response and progression-free survival. Never-smokers among the PD-L1 $\geq$50% subgroup comprise the only population identified that derived an apparent survival benefit with treatment intensification.

ABSTRACT

Importance: Single-agent PD-(L)1 blockade (IO) alone or in combination with

chemotherapy (Chemotherapy-IO) are approved first-line therapies in patients with

advanced lung adenocarcinomas (LUADs) with PD-L1 expression $\geq$1%. These

regimens have not been compared prospectively. **Objectives:** The primary objective

was to compare first-line efficacies of single-agent IO to Chemotherapy-IO in patients

with advanced LUADs. Secondary objectives were to explore if clinical, pathologic, and

genomic features were associated with differential response to Chemotherapy-IO vs IO.

Setting: Multicenter retrospective cohort study. **Participants:** Patients with advanced

LUADs with tumor PD-L1 $\geq$1% treated with first-line Chemotherapy-IO or IO.

Exposures: Chemotherapy-IO vs IO therapy. **Main outcomes:** Objective response rate

(ORR), progression-free survival (PFS) and overall survival (OS). **Results:** The cohort

analyzed included 874 patients who received first-line treatment for PD-L1-positive

advanced LUAD without sensitizing *EGFR* or *ALK* alterations. Relative to IO,

Chemotherapy-IO was associated with improved ORR (44% vs 35%, p=0.005) and PFS

in patients with tumor PD-L1$\geq$1% (HR 0.75, 95% CI 0.0.61-0.92, p=0.005) or PD-

L1$\geq$50% (ORR 55% vs 38%, p<0.001; PFS HR 0.74 95%CI 0.56-0.97, p=0.032). Using

propensity-adjusted analyses, only never smokers in the PD-L1 $\geq$50% subgroup derived

a differential survival benefit from Chemotherapy-IO vs IO (p=0.03). Among patients

with very high tumor PD-L1 expression ($\geq$90%) there were no differences in outcome

between treatment groups. No genomic factors conferred differential survival benefit to

Chemotherapy-IO vs IO. **Conclusions and Relevance:** While the addition of

chemotherapy to PD-(L)1 blockade increases the probability of initial response, never-

smokers with tumor PD-L1 $\geq$50% comprise the only population identified that derived an

apparent survival benefit with treatment intensification.

Introduction

Drugs that inhibit PD-1 or PD-L1 (PD-(L)1 blockade) have transformed the treatment landscape for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. In 2022, there are several US Food and Drug Administration-approved first-line PD-(L)-1 blockade regimens alone (IO) or in combination with platinum-doublet chemotherapy (Chemotherapy-IO), all of which demonstrated clinical benefit compared to chemotherapy[1-7]. The increased breadth of treatment options in newly diagnosed advanced lung cancer and lack of published head-to-head trials makes regimen selection challenging. It is unclear if certain populations might derive similar or greater clinical benefit from IO monotherapy than Chemotherapy-IO, and might thereby avoid the potential toxicities of chemotherapy.

Prior studies have identified clinical and genomic factors associated with efficacy of PD-(L)1 blockade. Eastern Cooperative Oncology Group (ECOG) performance status, smoking history, PD-L1 expression, and tumor mutational burden (TMB) influence clinical activity and outcomes[8-10]. NSCLCs harboring mutations in *STK11* and/or *KEAP1* have worse outcomes to PD-(L)1 blockade, particularly among *KRAS*-mutant NSCLCs[11]. In these cases, addition of chemotherapy might overcome IO resistance[11]. Conversely, other factors such as poor performance status may limit tolerability of chemotherapy and negate potential additive anti-cancer activity of combination therapy[12].

We posited that clinical, pathologic, and molecular analyses of a real-world patient population could identify patient subpopulations that might differentially benefit from IO vs Chemotherapy-IO in the first-line setting. In order to address biases and

differences in baseline characteristics between the IO and Chemotherapy-IO groups,

we performed propensity-adjusted analyses in 874 patient cases of lung

adenocarcinoma (LUAD) without *EGFR* or *ALK*-sensitizing alterations treated with IO or

Chemotherapy-IO at two institutions.

METHODS

Patients

After institutional review board approval, patients with advanced LUAD from Memorial

Sloan Kettering Cancer Center [MSK] and Dana-Farber Cancer Institute [DFCI]

between 2011-2020 were assessed in this retrospective analysis. Only patients with

advanced lung adenocarcinoma treated in the first-line with IO or Chemotherapy-IO

were eligible for analysis (**eFigure 1 in the Supplement**).

PD-L1 expression (tumor proportion score) was evaluated in all patients included

in the study and reported as the percentage of tumor cells with membranous staining as

previously described[13]. For genomic analyses, only patients with genomic sequencing

by MSK-IMPACT (MSK) or OncoPanel (DFCI) NGS panels were included[14,15]

(**eMethods in the Supplement**). TMB was harmonized for comparison as previously

published (**eMethods in the Supplement**)[16]. Patients with tumors with PD-L1 <1% or

harboring sensitizing *EGFR* or *ALK* alterations were excluded. Pre-planned analyses in

PD-L1 1-49% and $\geq$50% subgroups were conducted to align with current first-line

treatment guidelines[17]. The primary outcomes were objective response rate (ORR),

progression-free survival (PFS), and overall survival (OS).

Statistical Analysis

Descriptive statistics were used to describe the analysis population by treatment group

(Chemotherapy-IO vs IO). Differences in baseline characteristics by group were

evaluated using the Wilcoxon rank sum test, Fisher's exact test, or Pearson's Chi-

squared test as appropriate.

Patients who did not experience progression or death by the data lock date

(October 21st, 2021) were censored at date of last assessment. Investigator-assessed

ORR was defined as the rate of partial response + complete response. Real-world

investigator-assessed PFS was assessed from the date the patient began therapy to

the date of progression as previously described as per RECIST v1.1[18-20]. OS was

calculated from treatment start date until date of death or last assessment. Kaplan-

Meier curves and log-rank test statistics were computed to compare PFS and OS

between groups.

We conducted propensity score modelling for treatment group assignment using

a logistic regression model with the following potential prognostic factors as categorical

variables: age ($\geq$65 vs <65), Eastern Cooperative Oncology Group performance status

(ECOG; scores 2-3 vs scores 0-1), smoking status (current/former smokers vs. never

smokers), PD-L1 tumor proportion score percentage (PD-L1 $\geq$50% vs PD-L1 1-49%),

and presence of liver or brain metastases at baseline. To account for the potential

difference in treatment assignment, we conducted inverse probability weighted (IPW)

Cox proportional hazards models using the estimated propensity scores. Three sets of

IPW Cox models were explored. The first model (**main effects model**) contained

treatment group along with clinical categorical variables (age, ECOG, smoking status,

PD-L1 %, baseline liver metastases and baseline brain metastases) to examine the

overall treatment effects on PFS and OS. The second model (**treatment interaction**

model) further included interactions between treatment group and clinical variables to

examine treatment effect modifications, to identify subgroups for differential benefit of

Chemotherapy-IO vs IO. The third model was restricted to patients with genomic data

available, building off our second model (**treatment interaction model, genomics**

analysis cohort) with the additions of the following categorical variables: harmonized

TMB score (see **eMethods in the Supplement**) and five gene mutations (*KRAS*, *TP53*,

KEAP1, *STK11*, and *SMARCA4*), as well as their interactions with treatment group. The

five gene mutations were selected as they have previously been associated with IO

outcomes in lung cancer[21-23]. For each clinical subgroup of interest, we calculated the

hazard ratio for treatment group (Chemotherapy-IO vs IO) adjusting for all clinical

covariates included in the propensity score IPW Cox proportional hazards model, and

visualized these results using forest plots.

Analyses were conducted using R version 4.1.1 with the tidyverse (v1.3.1)[24],

gtsummary (v1.6.0)[25], survival (v3.3.1) and survminer (v0.4.9) packages[26].

Results

Patient Characteristics

Among all patients with advanced LUAD treated with Chemotherapy-IO or IO without a

targetable driver alteration in *EGFR* or *ALK*, 874 patients met criteria for inclusion

(**eFigure 1 in the Supplement**). Median follow-up for the clinical analysis cohort was 23

months (IQR: 12, 38); 397 (45%) patients were treated with Chemotherapy-IO and 477

(55%) were treated with IO (**Table 1**). Relative to the Chemotherapy-IO group, patients

in the IO group were slightly older (median age 69 vs 67, p<0.001) with a more frequent

and heavier smoking history (median pack years 30 vs. 25 p=0.022) (**Table 1**). PD-L1

high expression (≥50%) was enriched within the IO group relative to the Chemotherapy-

IO group (84% vs 29% with PD-L1 high, p<0.001) (**eFigure 2A in the Supplement**)[17].

Median harmonized TMB score (0.09 vs -0.05, p=0.023) was also significantly higher in

the IO group (**eFigure 2B in the Supplement**). Other baseline clinical factors such as

ECOG performance status and sex were similarly distributed between the

Chemotherapy-IO and IO groups (**Table 1**).

Clinical Outcomes

Among 874 patients with PD-L1 ≥1% LUAD who were treated with Chemotherapy-IO or

IO in the first-line setting, Chemotherapy-IO was associated with improved ORR (44%

vs 35%, p=0.005) (**Figure 1A**) and improved PFS (median PFS 6.9 (95% CI: 6.0, 8.5)

vs 4.9 months (95% CI: 4.0, 5.8), p=0.015) (**Figure 1B**). There was no difference in OS

between the Chemotherapy-IO vs IO groups (median OS 17 months, 95% CI: 15, 22) vs

20 months (95% CI: 17, 24), p=0.50) (**Figure 1C**). Examining subgroups of interest, age

<65 (HR 0.59, 95%CI 0.42-0.8), and never smoking status (0.43 95%CI 0.22-0.83) were

particularly associated with improved PFS among patients on Chemotherapy-IO (**Figure**

1D). No subgroup conferred differential survival benefit to Chemotherapy-IO vs IO

(**Figure 1E**).

In the IPW propensity-adjusted analysis, current/former smokers (OR 0.48,

95%CI 0.28-0.79, p=0.004) those with tumor PD-L1 ≥50% (OR 0.07, 95% CI 0.05-0.10,

p<0.001) were more likely to receive IO than Chemotherapy-IO (**eTable 1 in the**

Supplement). The results for the main effects model are shown in **eTable 2 and**

eTable 3 in the Supplement. In the treatment interaction model, Chemotherapy-IO was

associated with superior PFS compared to IO alone (HR 0.38, 95% CI 0.17-0.86,

p=0.020) (**eTable 4 in the Supplement**). No subgroups demonstrated differential PFS

benefit for Chemotherapy-IO or IO (**eTable 4 in the Supplement**). There was no OS

benefit associated with Chemotherapy-IO (HR 0.92, 95% CI 0.42-2.00, p=0.824)

(**eTable 5 in the Supplement**). No subgroups demonstrated differential OS benefit to

Chemotherapy-IO or IO (**eTable 5 in the Supplement**). In sum, among patients with

PD-L1 ≥1%, Chemotherapy-IO demonstrated a PFS benefit in a propensity-matched

analysis; however, there was no OS benefit associated with Chemotherapy-IO

compared to IO monotherapy.

Clinical Outcomes by PD-L1 Subgroup

Among 519 patients with tumor PD-L1 ≥50%, Chemotherapy-IO was associated

with improved ORR (55% vs 38%, p<0.001) (**Figure 2A**) and PFS (median PFS 10.0

(95% CI: 6.9, 16.0) vs 4.9 months (95% CI: 3.9, 6.2), p=0.002) (**Figure 2B**). There was

no significant difference in OS between the Chemotherapy-IO vs IO groups (median OS

32 (95% CI: 20, not reached (NR)) vs 20 months (95% CI: 17, 26), p=0.40) (**Figure 2C**).

Examining subgroups of interest, never-smokers (HR 0.29, 95%CI 0.16, 0.55) and

younger patients <65 years of age (HR 0.47 95%CI 0.31, 0.71), had improved PFS to

Chemotherapy-IO vs IO (**Figure 2D**).

In the IPW propensity-adjusted analysis, patients who were younger (<65 years

of age) (HR 0.58, 95%CI 0.38-0.90, p=0.015) or who were never-smokers (HR 0.52,

95% CI 0.28- 1.01, p=0.045) were more likely to receive Chemotherapy-IO (**eTable 6 in**

the Supplement). The results for the main effects model are shown in **eTable 7 and**

eTable 8 in the Supplement.

We found significant treatment effect modification factors shown in the treatment

interaction model in this PD-L1≥50% subgroup (**eTable 9 in the Supplement**).

Specifically, the Chemotherapy-IO PFS benefit over IO alone was more evident in

never-smokers (p=0.0089) (**eTable 9 in the Supplement**). Age was identified as a

significant treatment modifier as well (p=0.0325, **eTable 9 in the Supplement**).

Specifically, the Chemotherapy-IO benefit over IO alone was more evident in the

younger age group (<65 years) (**eTable 9 in the Supplement**). There was no significant

difference in OS for Chemotherapy-IO vs IO overall (HR 0.36, 95%CI 0.12-1.10,

p=0.0718) (**eTable 10 in the Supplement**). Never-smokers derived an OS benefit to

Chemotherapy-IO vs IO (HR 2.98, 95%CI 1.08-7.9, p=0.034) (**eTable 10 in the**

Supplement). Examining clinical outcomes in these subgroups in greater detail, ORR in

never-smokers was higher with Chemotherapy-IO vs IO group (76% vs 20%, p<0.001,

respectively) (**Figure 3A**). Median PFS among never-smokers in the Chemotherapy-IO

vs IO group was 10.0 months vs 2.2 months, respectively (**Figure 3B**). ORR among

patients <65 years of age in the Chemotherapy-IO vs IO groups was higher (63% vs

40%, respectively; p=0.004) (**Figure 3D**). Median PFS among <65 years of age in the

Chemotherapy-IO vs IO group was 17.0 months vs 4.6 months, respectively (**Figure**

3E). Taken together, these results suggest that in the PD-L1 $\geq$50% subgroup, there was

a PFS benefit in never-smokers and in younger adults, and OS benefit in never-

smokers favoring Chemotherapy-IO compared to IO.

Next, since very high PD-L1% ($\geq$90%) has previously been associated with

improved outcomes to IO[27], we explored this group in our dataset. Among patients with

very high tumor PD-L1 expression ($\geq$90%, N=214) there was no difference in ORR

(p=0.2) (**eFigure 3A in the Supplement**), PFS (p=0.15) (**eFigure 3B in the**

Supplement) or OS (p=0.4) (**eFigure 3C in the Supplement**) between the

Chemotherapy-IO or IO groups.

Lastly, in the PD-L1 1-49% subgroup (N=355 patients), Chemotherapy-IO was

associated with improved ORR (39% vs 19%, p<0.001) (**eFigure 4A in the**

Supplement) and PFS (median PFS 6.2 (95% CI: 5.5, 7.5) vs 4.4 months (95% CI: 3.4,

6.7), p=0.016) (**eFigure 4B in the Supplement**) compaed to IO. There was no

difference in OS between the Chemotherapy-IO vs IO groups (median OS 15 (95% CI:

13, 19) vs 17 months (95% CI: 10, 24), p=0.7) (**eFigure 4C in the Supplement**). IPW

propensity-adjusted analysis and treatment interaction models for the PD-L1 subgroup

are presented in **eTables 11-15 in the Supplement;** there was no differential benefit to

Chemotherapy-IO compared to IO in this subgroup for PFS or OS in any subgroup

examined.

Differential genomic biomarkers of response to Chemotherapy-IO vs IO

There were 579 patients with tumor PD-L1 ≥1% who were treated with

Chemotherapy-IO (N=263) or IO (N=316) and underwent genomic sequencing

(**eFigure1 in the Supplement**, genomic analysis cohort). Median follow-up for the

genomic analysis cohort was 24 months (IQR: 13, 40). Patient baseline characteristics

for the genomic analysis cohort were similar to the clinical analysis cohort (**eTable 16 in**

the Supplement).

There were no differences in ORR between Chemotherapy-IO and IO within

different mutation subgroups of interest in *KRAS*, *TP53*, *SMARCA4*, *KEAP1*, *STK11, or*

TMB (**Figure 4A**). In propensity-adjusted analyses, significant treatment effect modifiers

were found. Specifically, the Chemotherapy-IO benefit over IO alone was more evident

in patients with higher harmonized TMB score (p=0.002) (**eTable 17 in the**

Supplement). Conversely, the Chemotherapy-IO benefit over IO alone was reduced in

patients with *SMARCA4* mutations (p=0.011) (**eTable 17 in the Supplement**). No

significant differential OS benefit to Chemotherapy-IO vs IO was found among patients

with mutations in *KRAS*, *KEAP1*, *STK11*, or *TP53* or among TMB thresholds (**eTable 18**

in the Supplement). Examining the significant covariates conferring differential initial

benefit to Chemotherapy-IO vs IO further, there were no differences in PFS or OS

among patients with either high or low median TMB (**Figure 4B-E**). Patients with

SMARCA4 had numerically improved median PFS (**Figure 4F**) and OS (**Figure 4G**) to

IO compared to Chemotherapy-IO.

Discussion and conclusion

We examined the efficacy of IO compared to treatment intensification with

Chemotherapy-IO, in the context of key clinical and molecular features of LUAD. Within

the PD-L1 $\geq$50% subgroup, we found the addition of chemotherapy to PD-(L)1 blockade

led to improvements in ORR and PFS, but this only translated into an OS benefit in

never-smokers. The only population that did not derive any initial benefit to

Chemotherapy-IO over IO was the PD-L1 very high ($\geq$90%) subgroup.

Our analyses inform potential rational strategies to select and sequence available

therapies for patients with advanced lung cancers without targetable driver mutations.

The lack of superior survival with Chemotherapy-IO compared to IO supports the notion

that, biologically, chemotherapy and immunotherapy may be working independently and

additively rather than generating synergistic immunologic activity[28]. The addition of

chemotherapy increases the probability of initial response in a heterogenous patient

population with differential sensitivity to chemotherapy and immunotherapy, but long-

term benefit appears largely driven by whether PD-(L)1 blockade generates durable

anti-tumor immunity. The lack of OS benefit with Chemotherapy-IO compared to IO in

our overall study population is also supported by recent clinical analyses of real-world

and randomized-controlled trials in patients with PD-L1 $\geq$50% non-squamous NSCLC

[18,29]. In these circumstances, deeper investigation of clinical and genomic factors

associated with differential benefit with Chemotherapy-IO compared to IO is helpful to

optimize regimen selection.

We initially hypothesized that distinct clinical and molecular characteristics

previously associated with IO resistance (for example, baseline liver metastases,

STK11, and/or *KEAP1* mutations) might distinguish patient populations that would

benefit from treatment intensification with Chemotherapy-IO [11]. Contrary to our

hypothesis, we found that while factors such as liver metastases and *STK11* mutations

were associated with poor response overall, they did not confer superior long-term

benefit from Chemotherapy-IO. Thus, treatment escalation with chemotherapy may not

be sufficient or indicated solely based upon these factors. Conversely, predictors of

durable benefit from IO such as very high PD-L1% ($\geq$90%) may be a useful indicators of

when IO monotherapy is appropriate[30]. For this select group of patients, we found no

difference in initial response between the Chemotherapy-IO or IO groups. Interestingly,

our study also found that patients with *SMARCA4* mutations experienced better

response rates and PFS with IO compared to Chemotherapy-IO. The clinical implication

of this observation is supported by prior studies, which have identified *SMARCA4*

mutation as a poor prognostic factor, potentially associated with resistance to

chemotherapy[31,32] but improved response to IO [17]. However, only 12% of patients had

SMARCA4 mutations. More extensive molecular and gene expression analyses may be

helpful in determining if specific genomic signatures benefit differentially from

Chemotherapy-IO vs IO, but these analyses require much larger sample size for

adequate power in the face of multiple hypothesis testing.

Never smoking status emerged as the primary factor associated with survival

benefit favoring Chemotherapy-IO within the PD-L1 $\geq$50% subgroup. Prior studies have

found a correlation between smoking history and increased TMB and that smoking

history could be a potential clinical surrogate for TMB[33,34]. However, here we found that

even when accounting for TMB in a propensity adjusted model, smoking status

remained a distinct predictive factor. Smoking history is a readily available biomarker

that could be of value in determining regimen selection. Our analysis suggests that

Chemotherapy-IO should be strongly considered for never-smokers even in the

presence of high TMB and/or PD-L1 expression. Further work is needed to identify the

underlying biologic basis for this pattern.

The increased response rate and PFS benefit generally observed with

Chemotherapy-IO suggests that therapeutic escalation could have an important role in

aggressive or extensive disease. Here, the addition of chemotherapy could help provide

more immediate symptom relief. Further, these patients may not otherwise have the

opportunity to receive salvage chemotherapy after progression on immunotherapy. In

this scenario, initial disease control with chemotherapy could create a window of

disease control to enable the more gradual effects of IO to become operant. Notably,

however, in the setting of brain or liver metastases, we did not find any clinical benefit

from the addition of chemotherapy to IO, consistent with prior analysis[35]. In this setting,

it is unclear if the added toxicity that comes with chemotherapy may abrogate the

potential clinical benefits. Further investigation is also needed to understand the precise

impact of volume of disease on patient outcomes.

Our study is a retrospective analysis with the associated limitations, but we

sought to minimize inherent bias by including two large institutions and by applying

robust propensity-matching methodology. The modest sample size of the PD-L1 1-49%

subgroup, especially within the patients who received single-agent IO limited the power

of the analysis for this sub-population. Despite these limitations, our study is the first to

comprehensively study the comparative effectiveness of Chemotherapy-IO across all

relevant PD-L1 subgroups, integrating TMB and genomic analyses for the first time.

Our study highlights the critical nature of ongoing clinical trials prospectively

evaluating the comparative effectiveness of anti-PD-(L)1 with and without chemotherapy

(NCT03793179, NCT04547504). Our population included patients often not well-

represented in randomized-controlled trials. These trials exclude patients with ECOG

performance status of ≥2 and patients with active, untreated, or symptomatic brain

metastases. Our study population comprised 15% with ECOG performance status ≥2

and 30% with baseline brain metastases.

In conclusion, we observed improvements in ORR and PFS associated with

Chemotherapy-IO compared to IO, particularly in young, never-smokers. Never smoking

status in the PD-L1 $\geq$50% subgroup was the only characteristic in which ORR and PFS

improvement translated into a survival benefit. No genomic alterations favored overall

survival with Chemotherapy-IO compared to IO. Our findings demonstrate that the

addition of chemotherapy to PD-(L)1 blockade generally increases the probability of

initial response, but leads to improved survival only among never-smokers in the PD-L1

≥50% subgroup.

Figure Legends

Figure 1. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade (Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-L1≥1%. A. Objective response rate, **B.** Progression-free survival (PFS), and **C.** Overall survival (OS) among patients with tumor PD-L1≥1% who received first-line Chemotherapy-IO (N=397) vs IO (N=477). **D.** PFS and **E.** OS analysis for Chemotherapy-IO vs IO adjusting for co-variates of interest among different subgroups. Median survival times presented with confidence intervals in brackets. ECOG; Eastern Cooperative Oncology Group performance status. HR; hazard ratio. 95%CI; 95% confidence intervals.

Figure 2. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade (Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-L1≥50%. A. Objective response rate, **B.** Progression-free survival and **C.** Overall survival among patients with tumor PD-L1≥50% who received first-line Chemotherapy-IO (N=117) vs IO (N=402). **D.** PFS and **E.** OS analysis for Chemotherapy-IO vs IO adjusting for co-variates of interest among different subgroups. Median survival times presented with confidence intervals in brackets. ECOG; Eastern Cooperative Oncology Group performance status. HR; hazard ratio. 95%CI; 95% confidence intervals.

Figure 3. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-

L1$\geq$50% in subgroups of interest. A. Objective response rate, **B.** Progression-free

survival (PFS), and **C.** Overall survival (OS) between Chemotherapy-IO vs IO groups in

never smokers with tumor PD-L1$\geq$50%. **D.** Objective response rate, **E.** PFS, and **F.** OS

between Chemotherapy-IO vs IO groups in patients <65 years of age with PD-L1$\geq$50%.

Median survival times presented with confidence intervals in brackets.

Figure 4. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in the genomic analysis

cohort (PD-L1$\geq$1%). A. Objective response rate among genomic subgroups of interest

(*KRAS*, *TP53*, *SMARCA4*, *KEAP1*, *STK11, TMB)*. **B.** Progression-free survival (PFS)

and **C.** Overall survival (OS) of Chemotherapy-IO vs IO in TMB low groups. **D.** PFS and

E. OS for the TMB high groups. **F.** PFS and **G.** OS of Chemotherapy-IO vs IO in

patients with *SMARCA4* mutations. Median survival times presented with confidence

intervals in brackets. TMB; tumor mutational burden. TMB high; TMB >=50th percentile,

TMB low; TMB <50th percentile. Mut; mutated. WT; wild type. Mut; mutated. WT; wild

type. Median survival times presented with confidence intervals in brackets.

Supplemental Figure Legends

eFigure 1. Cohort assembly.

A total of N=3777 patients treated with either Chemotherapy-IO or IO treated between

1/10/17 and 9/8/20. Chemotherapy-IO; Combination PD(L)-1 blockade and platinum

chemotherapy. IO; single agent PD(L)-1 blockade.

eFigure 2. Median PD-L1 and harmonized tumor mutational burden (TMB)

between chemotherapy plus PD-(L)1 blockade (Chemotherapy-IO) vs single-agent

PD-(L)1 blockade (IO) groups. A. Box plots of tumor PD-L1 expression and **B.** Median

TMB between Chemotherapy-IO and IO. ***$p < 0.001$

eFigure 3. Outcomes to chemotherapy plus PD-(L)1 blockade (Chemotherapy-IO)

vs single-agent PD-(L)1 blockade (IO) among patients with PD-L1 $\geq$90%. A.

Objective response rate, **B.** Progression-free survival and **C.** Overall survival.

Chemotherapy-IO and IO. Chemotherapy-IO; Combination PD(L)-1 blockade and

platinum chemotherapy. IO; single agent PD(L)-1 blockade.

eFigure 4. Comparative effectiveness of chemotherapy plus PD-(L)1 blockade

(Chemotherapy-IO) vs single-agent PD-(L)1 blockade (IO) in patients with PD-L1 1-

49%. A. Objective response rate, **B.** Progression-free survival (PFS), and **C.** Overall

survival (OS) among Chemotherapy-IO vs IO groups. **D.** PFS and **E.** OS analysis for

Chemotherapy-IO vs IO adjusting for co-variates of interest among different subgroups.

ECOG; Eastern Cooperative Oncology Group performance status. Median survival

times presented with confidence intervals in brackets. HR; hazard ratio. 95%CI; 95%

confidence intervals.

References

1.   Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus
Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. *New England Journal*
of Medicine. 2018;378(22):2078-2092.
2.   Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in
Advanced Non-Small-Cell Lung Cancer. *N Engl J Med.* 2019;381(21):2020-2031.
3.   Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab
combined with two cycles of chemotherapy in patients with non-small-cell lung
cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol. 2021;22(2):198-211.
4.   Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line
Treatment of PD-L1–Selected Patients with NSCLC. *New England Journal of*
Medicine. 2020;383(14):1328-1339.
5.   Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment
of Metastatic Nonsquamous NSCLC. *New England Journal of Medicine.*
2018;378(24):2288-2301.
6.   Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy
versus chemotherapy alone in non-small cell lung cancer: a randomized,
controlled, double-blind phase 3 trial. *Nature Medicine.* 2022;28(11):2374-2380.
7.   Reck M, Rodríguez–Abreu D, Robinson AG, et al. Updated Analysis of
KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for
Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of
50% or Greater. *Journal of Clinical Oncology.* 2019;37(7):537-546.
8.   Hellmann MD, Nathanson T, Rizvi H, et al. Genomic Features of Response to
Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung
Cancer. *Cancer Cell.* 2018;33(5):843-852.e844.
9.   Sehgal K, Gill RR, Widick P, et al. Association of Performance Status With
Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With
Pembrolizumab Monotherapy. *JAMA Network Open.* 2021;4(2):e2037120-
e2037120.
10.   Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in
patients with non-small-cell lung cancer and very high PD-L1 expression. *Ann*
Oncol. 2019;30(10):1653-1659.
11.   Ricciuti B, Arbour KC, Lin JJ, et al. Diminished Efficacy of Programmed Death-
(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is
Affected by KRAS Mutation Status. *J Thorac Oncol.* 2022;17(3):399-410.
12.   Khaki AR, Glisch C, Petrillo LA. Immunotherapy in Patients With Poor
Performance Status: The Jury Is Still Out on This Special Population. *JCO*
Oncology Practice. 2021;17(9):583-586.
13.   Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of
PD-L1 expression in patients with lung adenocarcinomas. *Ann Oncol.*
2020;31(5):599-608.

14. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated
Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization
Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor
Molecular Oncology. *J Mol Diagn.* 2015;17(3):251-264.
15. Garcia EP, Minkovsky A, Jia Y, et al. Validation of OncoPanel: A Targeted Next-
Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
Arch Pathol Lab Med. 2017;141(6):751-758.
16. Vokes NI, Liu D, Ricciuti B, et al. Harmonization of Tumor Mutational Burden
Quantification and Association With Response to Immune Checkpoint Blockade
in Non-Small-Cell Lung Cancer. *JCO Precis Oncol.* 2019;3.
17. Ettinger DS, Wood DE, Aisner DL, et al. Non–Small Cell Lung Cancer, Version
3.2022, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National
Comprehensive Cancer Network.* 2022;20(5):497-530.
18. Pérol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in
combination with platinum-doublet chemotherapy in first-line (1L) non-squamous
non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-
world data. *Annals of Oncology.* 2022;33(5):511-521.
19. Curtis MD, Griffith SD, Tucker M, et al. Development and Validation of a High-
Quality Composite Real-World Mortality Endpoint. *Health Serv Res.*
2018;53(6):4460-4476.
20. Griffith SD, Tucker M, Bowser B, et al. Generating Real-World Tumor Burden
Endpoints from Electronic Health Record Data: Comparison of RECIST,
Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-
World Progression in Non-Small Cell Lung Cancer. *Adv Ther.* 2019;36(8):2122-
2136.
21. Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment Outcomes and Clinical
Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung
Cancer. *Clin Cancer Res.* 2021;27(8):2209-2215.
22. Lin X, Wang L, Xie X, et al. Prognostic Biomarker TP53 Mutations for Immune
Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment
of Lung Adenocarcinoma. *Front Mol Biosci.* 2020;7:602328.
23. Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. The Genomic Landscape of
SMARCA4 Alterations and Associations with Outcomes in Patients with Lung
Cancer. *Clin Cancer Res.* 2020.
24. al We. Welcome to the Tidyverse. Journal of Open Source Software.
2019;4(43):1686.
25. Daniel D. Sjoberg KW, Michael Curry, Jessica A. Lavery and Joseph
Larmarange. Reproducable Summary Tabes with the gtsummary package. *The
R Journal.* 2021;13:1:570-580.
26. *Modeling Survival Data: Extending the Cox Model.* 2000.
27. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line
treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a
multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet.*
2021;397(10274):592-604.

28.   Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via
Patient-to-Patient Variability without Drug Additivity or Synergy. *Cell.*
2017;171(7):1678-1691.e1613.
29.   Akinboro O, Vallejo JJ, Mishra-Kalyani PS, et al. Outcomes of anti-PD-(L1)
therapy in combination with chemotherapy versus immunotherapy (IO) alone for
first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with
PD-L1 score 1-49%: FDA pooled analysis. *Journal of Clinical Oncology.*
2021;39(15_suppl):9001-9001.
30.   Ricciuti B, Arbour KC, Alessi JVM, et al. Association of a very high tumor
mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved
clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels
in non-small cell lung cancer. *Journal of Clinical Oncology.*
2021;39(15_suppl):9018-9018.
31.   Song S, Nguyen V, Schrank T, et al. Loss of SWI/SNF Chromatin Remodeling
Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. *Mol Cancer Res.*
2020;18(12):1777-1788.
32.   Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-Deficient Thoracic
Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated
Carcinomas Rather Than Primary Thoracic Sarcomas. *J Thorac Oncol.*
2020;15(2):231-247.
33.   Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with
tobacco smoking in human cancer. *Science.* 2016;354(6312):618-622.
34.   Wang X, Ricciuti B, Nguyen T, et al. Association between Smoking History and
Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. *Cancer Res.*
2021;81(9):2566-2573.
35.   Pérol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in
combination with platinum-doublet chemotherapy in first-line (1L) non-squamous
non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-
world data. *Ann Oncol.* 2022.
580

581
582

Conflicts of interest:
JEC has consulted for: AstraZeneca, BMS, Genentech, Merck, Flame Biosciences, Regeneron-Sanofi, Guardant Health, Arcus Biosciences and also declared research funding to institution from: AstraZeneca, BMS, Genentech, Merck, Novartis. CMR has consulted with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. GJR reports institutional research support from Mirati, Lilly, Takeda, Merck, Roche, Pfizer, and Novartis. MGK reports honoraria from AstraZeneca, Pfizer, Merus, and BerGenBio. MDH reports grants from BMS; and personal fees from Achilles; Adagene; Adicet; Arcus; AstraZeneca; Blueprint; BMS; DaVolterra; Eli Lilly; Genentech/Roche; Genzyme/Sanofi; Janssen; Immunai; Instil Bio; Mana Therapeutics; Merck; Mirati; Natera; Pact Pharma; Shattuck Labs; and Regeneron; as well as equity options from Factorial, Immunai, Shattuck Labs, Arcus, and Avail Bio. A patent filed by Memorial Sloan Kettering related to the use of tumor mutational burden to predict response to immunotherapy (PCT/US2015/062208) is pending and licensed by PGDx. Subsequent to the completion of this work, MDH began as an employee (and equity holder) at AstraZeneca. MMA reports that he was a consultant to: Bristol-Myers Squibb, Merck, Genentech, AstraZeneca, Mirati, Novartis, Blueprint Medicine, Abbvie, Gritstone, NextCure, EMD Serono and received research funding (to institute) from: Bristol-Myers Squibb, Eli Lilly, Genentech, AstraZeneca, Amgen. AJS reports consulting/advising role to J&J, KSQ therapeutics, BMS, Merck, Enara Bio, Perceptive Advisors, Oppenheimer and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics, Lyell Immunopharma and Heat Biologics, research funding from GSK (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS (Inst), Harpoon Therapeutics (Inst) and Amgen (Inst). AJS reports consulting/advising role to J&J, KSQ therapeutics, BMS, Merck, Enara Bio, Perceptive Advisors, Oppenheimer and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics, Lyell Immunopharma and Heat Biologics. Research funding: GSK (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS (Inst), Harpoon Therapeutics (Inst) and Amgen (Inst).

Funding:
AE effort funded by the Canadian Institutes of Health Research, the Royal College of Surgeons and Physicians of Canada, and the Henry R. Shibata Fellowship. XW effort funded by: National Institutes of Health grant U01CA209414. MMA effort was funded by: V Foundation, Elva J. and Clayton L. McLaughlin Fund for Lung Cancer Research. This study was funded by National Institute of Health grants (cancer center grant P30CA008748 to MSKCC) and philanthropy (grants from John and Georgia DallePezze to MSKCC, The Ning Zhao & Ge Li Family Initiative for Lung Cancer Research and New Therapies, and the James A. Fieber Lung Cancer Research Fund).

Acknowledgements: The authors wish to acknowledge Clare Wilhelm for editorial support. The authors wish to acknowledge the support of the Center Core grant (P30 CA008748), the Molecular Diagnostics Service in the Department of Pathology, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology.

Table 1: Baseline characteristics

Characteristic	Overall, N = 874[1]	Chemo/IO, N = 397[1]	IO, N = 477[1]	p-value[2]
Site				0.088
DFCI	481 (55%)	206 (52%)	275 (58%)	
MSK	393 (45%)	191 (48%)	202 (42%)	
Age, median (IQR)	68 (60, 75)	67 (59, 72)	69 (61, 76)	**<0.001**
Sex				0.3
Female	494 (57%)	216 (54%)	278 (58%)	
Male	380 (43%)	181 (46%)	199 (42%)	
ECOG performance status				0.5
0-1	721 (82%)	321 (86%)	400 (84%)	
>= 2	129 (15%)	53 (14%)	76 (16%)	
Unknown	24 (3%)	23	1	
Pack years, median (IQR)	28 (10, 45)	25 (8, 42)	30 (15, 45)	**0.022**
Unknown	41	26	15	
Smoking Status				**<0.001**
Current/Former	767 (88%)	331 (83%)	436 (91%)	
Never	104 (12%)	64 (16%)	40 (8%)	
Unknown	3 (0%)	2 (1%)	1	
Baseline liver metastases	114 (13%)	43 (11%)	71 (15%)	0.068
Unknown	15	5	10	
Baseline brain metastases	225 (26%)	90 (23%)	135 (29%)	0.049
Unknown	21	8	13	
PD-L1 Status				**<0.001**
PD-L1 >=50	519 (59%)	117 (29%)	402 (84%)	
PD-L1 1-49	355 (41%)	280 (71%)	75 (16%)	
% PD-L1	60 (10, 85)	20 (5, 60)	80 (50, 90)	**<0.001**
Unknown	10	10	0	
Harmonized TMB score, median (IQR)	0.09 (-0.68, 0.65)	-0.05 (-0.73, 0.55)	0.09 (-0.53, 0.66)	**0.023**
Unknown	295 (34%)	134 (34%)	161 (34%)	

[1] n (%)
[2] Pearson's Chi-squared test; Wilcoxon rank sum test.
Chemo: Chemotherapy; DFCI: Dana-Farber Cancer Institute; ECOG: Eastern Cooperative Oncology Group; IO: Immunotherapy; MSK: Memorial Sloan Kettering Cancer Center; TMB: tumor mutational burden

PD-L1 ≥1%

Figure 2

PD-L1 ≥ 50%

Figure 3

Figure 4

A.

TMB low

B.

C.

TMB high

D.

E.

SMARCA4mut

F.

G.

Supplementary Material: Table of Contents

Supplemental Methods

Genomic sequencing – Memorial Sloan Kettering Cancer Center (MSK)

Biopsies from patients treated at MSK underwent next-generation sequencing (NGS) using the MSK-IMPACT platform as previously described[34]. Briefly, DNA was extracted from tumors and patient-matched blood samples. Bar-coded libraries were generated and sequenced for targeted all exons and select introns of a custom gene panel of 341 (version1), 410 (version 2), or 468 (version 3) genes. Samples were run through a custom pipeline to identify somatic alterations, including mutations and copy number alterations. Tumor mutational burden was calculated as previously described[35].

Genomic sequencing – Dana-Farber Cancer Institute (DFCI)

Targeted exome NGS (Profile) was carried out using the validated OncoPanel assay in the Center for Cancer Genome Discovery at the DFCI for 277 (POPv1), 302 (POPv2), or 447 (POPv3) cancer-associated genes. Variants were filtered to remove potential germline variants as previously published and annotated using Oncotractor as previously described. To remove additional germline noise, variants that were annotated as benign/likely benign in ClinVar or were present at a population maximum allele frequency of < 0.1% were excluded. Variants were retained in either case if they were annotated as confirmed somatic in at least two samples in COSMIC as previously described[36].

Harmonization of Tumor Mutation Burden

Tumor mutational burden was calculated at MSK and at DFCI as previously

described. To address differences in sequencing methodologies, we performed

harmonization of TMB as previously done[15]. TMB distributions were harmonized by

applying a normal transformation followed by standardization to z-scores, which enables

integration of datasets derived from different sequencing panels[15].

eTable 1: PD-L1≥1%: Propensity score analysis for Chemo-IO vs. IO determining likelihood of receiving Chemo-IO vs. IO

PD-L1≥1%: Propensity score analysis for Chemo/IO vs. IO determining likelihood of receiving Chemo/IO vs. IO			
Characteristic	**OR**[1]	**95% CI**[1]	**p-value**
>=65 vs. <65	0.77	0.54, 1.09	0.14
ECOG 2-3 vs. 0-1	0.85	0.53, 1.36	0.5
Current/Former Smoker vs. Never Smoker	0.48	0.28, 0.79	**0.004**
PD-L1 >=50 vs. 1-49	0.07	0.05, 0.10	**<0.001**
Baseline liver metastases	0.72	0.43, 1.18	0.2
Baseline brain metastases	0.85	0.57, 1.24	0.4
[1] OR = Odds Ratio, CI = Confidence Interval			

eTable 2: PD-L1≥1%: Propensity-adjusted Cox model for PFS – Main effects model

PD-L1 ≥1%: Propensity-adjusted Cox model for PFS - Main effects model			
Characteristic	HR[1]	95% CI[1]	p-value
Chemo + IO vs. IO	0.75	0.61, 0.92	**0.005**
>=65 vs. <65	1.29	1.06, 1.58	**0.013**
ECOG (2-3 vs. 0-1)	1.44	1.09, 1.90	**0.009**
Current/Former Smoker vs. Never Smoker	0.88	0.64, 1.21	0.4
PD-L1 >=50 vs. 1-49	0.74	0.61, 0.90	**0.003**
Baseline liver metastases	1.61	1.19, 2.17	**0.002**
Baseline brain metastases	1.05	0.83, 1.31	0.7
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 3: PD-L1 >1%: Propensity-adjusted Cox model for OS - Main effects model

PD-L1 >1%: Propensity-adjusted Cox model for OS - Main effects model			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	1.05	0.83, 1.33	0.7
>=65 vs. <65	1.44	1.14, 1.83	**0.002**
ECOG (2-3 vs. 0-1)	1.99	1.45, 2.74	**<0.001**
Current/Former Smoker vs. Never Smoker	1.29	0.93, 1.79	0.13
PD-L1 >=50 vs. 1-49	0.79	0.62, 0.99	**0.044**
Baseline liver metastases	1.48	1.05, 2.09	**0.025**
Baseline brain metastases	0.97	0.74, 1.27	0.8
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 4: PD-L1 >1%: Propensity-adjusted Cox model for PFS – Treatment interaction model

Propensity-adjusted Cox model for PFS (All patients)			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	0.38	0.17, 0.86	**0.020**
>=65 vs. <65	1.06	0.81, 1.39	0.7
ECOG (2-3 vs. 0-1)	1.46	1.05, 2.02	**0.025**
Current/Former Smoker vs. Never Smoker	0.66	0.37, 1.17	0.2
PD-L1 >=50 vs. 1-49	0.79	0.59, 1.06	0.12
Baseline liver metastases	1.61	1.13, 2.30	**0.009**
Baseline brain metastases	1.02	0.76, 1.36	0.9
Chemo + IO vs. IO * >=65 vs. <65	1.49	0.99, 2.25	0.055
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.91	0.51, 1.63	0.8
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	1.73	0.89, 3.35	0.11
Chemo + IO vs. IO * PD-L1 >=50 vs. 1-49	0.90	0.60, 1.34	0.6
Chemo + IO vs. IO * Baseline liver metastases	1.05	0.57, 1.92	0.9
Chemo + IO vs. IO * Baseline brain metastases	1.03	0.66, 1.63	0.9
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 5: PD-L1 ≥1%: Propensity-adjusted Cox model for OS – Treatment interaction model

Propensity-adjusted Cox model for OS (All patients)			
Characteristic	HR[1]	95% CI[1]	p-value
Chemo + IO vs. IO	0.92	0.42, 2.00	0.8
>=65 vs. <65	1.40	1.04, 1.89	**0.029**
ECOG (2-3 vs. 0-1)	2.27	1.58, 3.26	**<0.001**
Current/Former Smoker vs. Never Smoker	1.20	0.72, 2.00	0.5
PD-L1 >=50 vs. 1-49	0.82	0.60, 1.13	0.2
Baseline liver metastases	1.38	0.93, 2.05	0.11
Baseline brain metastases	0.91	0.66, 1.27	0.6
Chemo + IO vs. IO * >=65 vs. <65	1.07	0.66, 1.73	0.8
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.75	0.39, 1.45	0.4
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	1.17	0.61, 2.25	0.6
Chemo + IO vs. IO * PD-L1 >=50 vs. 1-49	0.92	0.58, 1.48	0.7
Chemo + IO vs. IO * Baseline liver metastases	1.16	0.57, 2.36	0.7
Chemo + IO vs. IO * Baseline brain metastases	1.14	0.66, 1.96	0.6
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 6: PD-L1≥50%: Propensity score analysis for Chemo-IO vs. IO determining likelihood of receiving Chemo-IO vs. IO

PD-L1≥50%: Propensity score analysis for Chemo/IO vs. IO determining likelihood of receiving Chemo/IO vs. IO			
Characteristic	**OR** [1]	**95% CI** [1]	**p-value**
>=65 vs. <65	0.58	0.38, 0.90	**0.015**
ECOG 2-3 vs. 0-1	0.94	0.50, 1.68	0.8
Current/Former Smoker vs. Never Smoker	0.52	0.28, 1.01	**0.045**
Baseline liver metastases	0.72	0.36, 1.34	0.3
Baseline brain metastases	0.84	0.51, 1.35	0.5
[1] OR = Odds Ratio, CI = Confidence Interval			

eTable 7: PD-L1 >50%: Propensity-adjusted Cox model for PFS - Main effects model

PD-L1 >50%: Propensity-adjusted Cox model for PFS - Main effects model			
Characteristic	HR[1]	95% CI[1]	p-value
Chemo + IO vs. IO	0.74	0.56, 0.97	**0.032**
>=65 vs. <65	1.34	1.03, 1.75	**0.027**
ECOG (2-3 vs. 0-1)	1.38	0.93, 2.04	0.11
Current/Former Smoker vs. Never Smoker	0.91	0.63, 1.32	0.6
Baseline liver metastases	1.70	1.17, 2.48	**0.005**
Baseline brain metastases	0.95	0.72, 1.27	0.7
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 8: PD-L1 ≥50%: Propensity-adjusted Cox model for OS - Main effects model

PD-L1 ≥50%: Propensity-adjusted Cox model for OS - Main effects model			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	1.02	0.73, 1.43	>0.9
>=65 vs. <65	1.51	1.10, 2.07	**0.011**
ECOG (2-3 vs. 0-1)	2.00	1.27, 3.14	**0.003**
Current/Former Smoker vs. Never Smoker	1.24	0.78, 1.98	0.4
Baseline liver metastases	1.66	1.08, 2.56	**0.020**
Baseline brain metastases	0.88	0.61, 1.25	0.5
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 9: PD-L1 >50%: Propensity-adjusted Cox model for PFS – Treatment interaction model

Propensity-adjusted Cox model for PFS			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	0.21	0.09, 0.49	**<0.001**
>=65 vs. <65	1.03	0.80, 1.32	0.8
ECOG (2-3 vs. 0-1)	1.35	0.97, 1.89	0.073
Current/Former Smoker vs. Never Smoker	0.57	0.37, 0.87	**0.009**
Baseline liver metastases	1.58	1.14, 2.20	**0.007**
Baseline brain metastases	0.99	0.76, 1.27	>0.9
Chemo + IO vs. IO * >=65 vs. <65	1.80	1.05, 3.09	**0.032**
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.93	0.39, 2.24	0.9
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	2.61	1.27, 5.35	**0.009**
Chemo + IO vs. IO * Baseline liver metastases	1.23	0.56, 2.71	0.6
Chemo + IO vs. IO * Baseline brain metastases	0.88	0.48, 1.62	0.7
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 10: PD-L1 ≥50%: Propensity-adjusted Cox model for OS – Treatment interaction model

Propensity-adjusted Cox model for OS			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	0.36	0.12, 1.10	0.072
>=65 vs. <65	1.37	1.03, 1.82	**0.032**
ECOG (2-3 vs. 0-1)	2.06	1.42, 2.98	**<0.001**
Current/Former Smoker vs. Never Smoker	0.78	0.50, 1.21	0.3
Baseline liver metastases	1.66	1.22, 2.27	**0.001**
Baseline brain metastases	0.96	0.72, 1.29	0.8
Chemo + IO vs. IO * >=65 vs. <65	1.28	0.66, 2.48	0.5
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.89	0.33, 2.39	0.8
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	2.93	1.08, 7.92	**0.034**
Chemo + IO vs. IO * Baseline liver metastases	0.99	0.37, 2.67	>0.9
Chemo + IO vs. IO * Baseline brain metastases	0.78	0.36, 1.72	0.5
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 11: PD-L1 1-49%: Propensity score analysis for Chemo-IO vs. IO determining likelihood of receiving Chemo-IO vs. IO

PD-L1 1-49%: Propensity score analysis for Chemo/IO vs. IO determining likelihood of receiving Chemo/IO vs. IO			
Characteristic	**OR[1]**	**95% CI[1]**	**p-value**
>=65 vs. <65	1.23	0.70, 2.14	0.5
ECOG 2-3 vs. 0-1	0.73	0.36, 1.57	0.4
Current/Former Smoker vs. Never Smoker	0.37	0.12, 0.90	**0.044**
Baseline liver metastases	0.76	0.35, 1.74	0.5
Baseline brain metastases	0.94	0.50, 1.80	0.8
[1] OR = Odds Ratio, CI = Confidence Interval			

eTable 12: PD-L1 1-49%: Propensity-adjusted Cox model for PFS - Main effects model

PD-L1 1-49%: Propensity-adjusted Cox model for PFS - Main effects model			
Characteristic	**HR**[1]	**95% CI**[1]	**p-value**
Chemo + IO vs. IO	0.77	0.56, 1.07	0.12
>=65 vs. <65	1.26	0.92, 1.73	0.14
ECOG (2-3 vs. 0-1)	1.53	1.05, 2.24	**0.027**
Current/Former Smoker vs. Never Smoker	0.84	0.48, 1.46	0.5
Baseline liver metastases	1.38	0.83, 2.28	0.2
Baseline brain metastases	1.30	0.90, 1.87	0.2
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 13: PD-L1 1-49%: Propensity-adjusted Cox model for OS - Main effects model

PD-L1 1-49%: Propensity-adjusted Cox model for OS - Main effects model			
Characteristic	HR[1]	95% CI[1]	p-value
Chemo + IO vs. IO	1.10	0.78, 1.54	0.6
>=65 vs. <65	1.41	0.99, 2.00	0.055
ECOG (2-3 vs. 0-1)	2.14	1.45, 3.18	**<0.001**
Current/Former Smoker vs. Never Smoker	1.49	0.90, 2.46	0.12
Baseline liver metastases	1.16	0.66, 2.02	0.6
Baseline brain metastases	1.22	0.81, 1.83	0.3
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 14: PD-L1 1-49%: Propensity-adjusted Cox model for PFS – Treatment interaction model

Propensity-adjusted Cox model for PFS			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	0.60	0.15, 2.36	0.5
>=65 vs. <65	1.22	0.69, 2.18	0.5
ECOG (2-3 vs. 0-1)	1.51	0.67, 3.40	0.3
Current/Former Smoker vs. Never Smoker	0.72	0.20, 2.54	0.6
Baseline liver metastases	1.49	0.58, 3.78	0.4
Baseline brain metastases	1.28	0.63, 2.58	0.5
Chemo + IO vs. IO * >=65 vs. <65	1.04	0.55, 1.98	0.9
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.98	0.41, 2.36	>0.9
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	1.32	0.36, 4.83	0.7
Chemo + IO vs. IO * Baseline liver metastases	0.89	0.32, 2.44	0.8
Chemo + IO vs. IO * Baseline brain metastases	1.04	0.48, 2.25	>0.9
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 15: PD-L1 1-49%: Propensity-adjusted Cox model for OS – Treatment interaction model

Propensity-adjusted Cox model for OS			
Characteristic	**HR**[1]	**95% CI**[1]	**p-value**
Chemo + IO vs. IO	2.74	0.87, 8.64	0.084
>=65 vs. <65	1.65	0.85, 3.23	0.14
ECOG (2-3 vs. 0-1)	3.11	1.43, 6.77	**0.004**
Current/Former Smoker vs. Never Smoker	2.55	1.01, 6.43	**0.047**
Baseline liver metastases	0.92	0.33, 2.53	0.9
Baseline brain metastases	1.09	0.49, 2.41	0.8
Chemo + IO vs. IO * >=65 vs. <65	0.76	0.36, 1.60	0.5
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.48	0.19, 1.17	0.11
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	0.43	0.16, 1.18	0.10
Chemo + IO vs. IO * Baseline liver metastases	1.62	0.53, 4.96	0.4
Chemo + IO vs. IO * Baseline brain metastases	1.41	0.59, 3.37	0.4
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 16: Baseline characteristics for genomic analysis cohort

Characteristic	Overall, N = 579[1]	Chemo/IO, N = 263[1]	IO, N = 316[1]	p-value[2]
Site				0.2
DFCI	319 (55%)	138 (52%)	181 (57%)	
MSK	260 (45%)	125 (48%)	135 (43%)	
Age	67 (60, 75)	66 (59, 73)	68 (60, 76)	**0.008**
Sex				0.7
Female	331 (57%)	148 (56%)	183 (58%)	
Male	248 (43%)	115 (44%)	133 (42%)	
ECOG				0.3
< 2	528 (93%)	231 (92%)	297 (94%)	
>= 2	38 (6.7%)	20 (8.0%)	18 (5.7%)	
Unknown	13	12	1	
Pack yrs	28 (10, 44)	25 (7, 40)	30 (15, 45)	**0.032**
Unknown	27	20	7	
Smoking Status				**0.002**
Current/Former	508 (88%)	218 (83%)	290 (92%)	
Never	70 (12%)	44 (17%)	26 (8.2%)	
Unknown	1	1	0	
Baseline liver metastases	81 (14%)	34 (13%)	47 (15%)	0.5
Baseline brain metastases	166 (29%)	68 (26%)	98 (31%)	0.2
Unknown	2	2	0	
PD-L1 Status				**<0.001**
PD-L1 1-49	243 (42%)	195 (74%)	48 (15%)	
PD-L1 >=50	336 (58%)	68 (26%)	268 (85%)	
Harmonized TMB score	0.09 (-0.68, 0.65)	-0.05 (-0.73, 0.55)	0.09 (-0.53, 0.66)	**0.023**
SMARCA4	71 (12%)	31 (12%)	40 (13%)	0.8
STK11	92 (16%)	55 (21%)	37 (12%)	**0.003**
KRAS	301 (52%)	136 (52%)	165 (52%)	>0.9
KEAP1	116 (20%)	57 (22%)	59 (19%)	0.4
TP53	351 (61%)	152 (58%)	199 (63%)	0.2

[1] n (%); Median (IQR)

[2] Pearson's Chi-squared test; Wilcoxon rank sum test

eTable 17: PD-L1 ≥1% Propensity-adjusted Cox model for PFS – Treatment interaction model

Propensity-adjusted Cox model for PFS			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	0.44	0.17, 1.15	0.093
>=65 vs. <65	1.14	0.83, 1.57	0.4
ECOG (2-3 vs. 0-1)	1.61	0.87, 2.99	0.13
Current/Former Smoker vs. Never Smoker	0.74	0.36, 1.51	0.4
PD-L1 >=50 vs. 1-49	0.67	0.48, 0.92	**0.013**
Baseline liver metastases	1.17	0.75, 1.82	0.5
Baseline brain metastases	1.05	0.74, 1.49	0.8
Chemo + IO vs. IO * >=65 vs. <65	1.26	0.76, 2.08	0.4
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.81	0.31, 2.15	0.7
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	1.49	0.64, 3.44	0.4
Chemo + IO vs. IO * PD-L1 >=50 vs. 1-49	1.05	0.65, 1.70	0.8
Chemo + IO vs. IO * Baseline liver metastases	1.46	0.71, 3.00	0.3
Chemo + IO vs. IO * Baseline brain metastases	0.75	0.42, 1.34	0.3
[1] HR = Hazard Ratio, CI = Confidence Interval			

eTable 18: PD-L1 ≥1% Propensity-adjusted Cox model for OS – Treatment interaction model

Propensity-adjusted Cox model for OS			
Characteristic	**HR[1]**	**95% CI[1]**	**p-value**
Chemo + IO vs. IO	0.74	0.28, 1.95	0.5
>=65 vs. <65	1.56	1.07, 2.28	**0.021**
ECOG (2-3 vs. 0-1)	2.07	1.16, 3.69	**0.013**
Current/Former Smoker vs. Never Smoker	1.16	0.57, 2.35	0.7
PD-L1 >=50 vs. 1-49	0.59	0.41, 0.85	**0.005**
Baseline liver metastases	1.07	0.66, 1.73	0.8
Baseline brain metastases	0.95	0.63, 1.44	0.8
Chemo + IO vs. IO * >=65 vs. <65	0.91	0.51, 1.63	0.8
Chemo + IO vs. IO * ECOG (2-3 vs. 0-1)	0.69	0.26, 1.85	0.5
Chemo + IO vs. IO * Current/Former Smoker vs. Never Smoker	1.25	0.52, 3.01	0.6
Chemo + IO vs. IO * PD-L1 >=50 vs. 1-49	1.52	0.87, 2.65	0.14
Chemo + IO vs. IO * Baseline liver metastases	1.49	0.69, 3.24	0.3
Chemo + IO vs. IO * Baseline brain metastases	1.02	0.53, 1.98	>0.9
[1] HR = Hazard Ratio, CI = Confidence Interval			

eFigure 1

eFigure 2

A.

B.

eFigure 3

PD-L1 ≥ 90%

PD-L1 1-49%